Baxter International Expands Dialyzers Facility in Alabama - Analyst Blog

By
A A A

Baxter International Inc. ( BAX ) revealed plans to expand its Opelika manufacturing plant in Alabama in order to expand the production of dialyzers, which are artificial kidneys capable of cleaning blood in end-stage renal disease (ESRD) patients.

BAX has been experiencing burgeoning demand for dialyzers across the globe as more people are getting inflicted by ESRD due to growing incidence of diabetes, blood pressure and other kidney-related diseases. It has been estimated that due to these reasons, the need for dialysis is growing at a fast rate of 6-7%.

Dialyzers are an important part of life-sustaining hemodialysis therapy (HD) for treating ESRD patients. With the help of this therapy, waste and excess fluids are excreted from the body by processing blood with the help of dialyzers. Thereafter, the purified blood is returned to the patients' body.

BAX intends to invest roughly $300 million in the Alabama plant for adding 230,000 square feet and several production lines. The expansion would need 200 additional workers at the plant by 2016, when the commercial production is scheduled to begin at the new lines. The plant currently employs 170 people.

Recently, pharmaceutical behemoth Pfizer Inc. ( PFE ) agreed to acquire a couple of marketed vaccines from BAX for $635 million. The two vaccines include meningitis vaccine NeisVac-C and tick-borne encephalitis vaccine FSME-IMMUN/TicoVac.

The two vaccines are sold in some European countries and other markets outside the U.S. As part of the deal, Pfizer will gain partial control of BAX's Orth facility in Austria where these life-saving vaccines are produced.

BAX is on the verge of splitting its business into two entities - biopharmaceuticals/bioscience and medical device. The company took the decision to split up its business in order to put greater management focus on the two segments, effectively commercialize product offerings, efficiently allocate resources to high growth areas, and bring flexibility in deciding on growth and investment strategies. The split-up is expected to be completed in mid-2015.

BAX's BioScience business will focus on immune deficiencies and blood-related disorders and includes the plan to form a partnership or sale of its drug development programs based on the flu and Lyme diseases. On the other hand, BAX's medical device business will continue to focus on intravenous (IV) solutions, injectable drugs, anesthetics, and other equipments.

BAX posted a 5.0% rise in adjusted net earnings to $692 million or $1.26 per share for the second quarter of 2014 from $659 million or $1.20 per share in the same quarter a year back. With this, earnings per share not only surpassed the company's previously issued guidance of $1.18 to $1.22 but also the Zacks Consensus Estimate by 5 cents.

Revenues in the quarter went up 16.2% to $4,264 million globally and exceeded the Zacks Consensus Estimate of $4,112 million. Excluding the $408 million contribution from the Gambro acquisition, revenues in the quarter grew 5%.

For the third quarter of 2014, BAX expects revenues to grow between 12 and 13%, barring the impact of foreign currency. The company also expects adjusted earnings in the range of $1.28 to $1.32 per share for the quarter. The current Zacks Consensus Estimate of $1.31 lies within the guided range.

For full year 2014, BAX now expects higher revenue growth of 10 to 11% compared with the prior view of 9 to 10%, excluding the impact of foreign exchange.

However, BAX narrowed its adjusted earnings per share guidance to $5.10 to $5.20 for the year from the earlier band of $5.05 and $5.25. The Zacks Consensus Estimate of $5.16 for the year lies within the guided range.

Currently, BAX retain a Zacks Rank #3 (Hold). Some better-ranked stocks in the medical products industry include ICU Medical, Inc. ( ICUI ) and Symmetry Medical, Inc. ( SMA ). ICU Medical carries a Zacks Rank #1 (Strong Buy) while Symmetry Medical retain a Zacks Rank #2 (Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PFIZER INC (PFE): Free Stock Analysis Report

BAXTER INTL (BAX): Free Stock Analysis Report

SYMMETRY MEDICL (SMA): Free Stock Analysis Report

ICU MEDICAL INC (ICUI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: HD , PFE , BAX , SMA , ICUI

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

270,887,127
    $93.89 unch
225,243,115
  • $40.93 ▼ 2.74%
135,900,109
  • $47.52 ▲ 1.80%
89,467,924
  • $5.35 ▼ 1.11%
85,105,358
  • $16.95 ▼ 0.53%
80,748,539
  • $39.80 ▼ 4.21%
68,491,586
  • $3.57 ▼ 1.79%
62,097,356
  • $100.96 ▼ 0.82%
As of 9/19/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com